Icure Pharmaceutical Incorporation

아이큐어175250KOSDAQSector: Chemicals & Materials

₩2,1000.47%Market cap ₩78.9BAs of Sep 4, 2026 close · updated once daily

Market cap

₩78.9B

#845 in KOSDAQ

Loss

PER not computable

2.99x

Sector median 0.71x

0.0%

Sector median 0.0%

Trading halted — grade display suspended

This stock is under a trading halt per KRX disclosure. Grade display resumes once trading resumes.

See withholding criteria →View source filing (DART) ↗

This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1-year closing price

Low ₩2,100High ₩2,870

Latest close

Price change by period

26.80%

Adjusted for 1 price-basis change(s) such as stock splits or reverse splits during the period.

As of the Sep 4, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

Financial strength

4.9/100

How much debt does it carry relative to equity?

270.0%

Sector median 65.6%

Sector low

highBottom 3.6% in sector

Can it cover what's due within a year?

58.8%

Sector median 153.1%

Sector low

highBottom 5.5% in sector

How much of revenue becomes profit?

-14.3%

Sector median 3.8%

Sector low

highBottom 9.6% in sector

How much did it earn on its own capital?

-127.5%

Sector median 3.6%

Sector low

highBottom 0.9% in sector

Source filing: annual report (consolidated) — view original ↗

Growth momentum

81.0/100

How much did revenue grow in a year?

20.5%

Sector median 0.2%

Sector low

highTop 10.8% in sector

Has it grown steadily over three years?

12.0%

Sector median -1.5%

Sector low

highTop 9.9% in sector

Did core profits grow in a year?

30.4%

Sector median -6.7%

Sector low

highTop 26.5% in sector

Are core profits higher than three years ago?

55.3%

Sector median -12.2%

Sector low

highTop 28.7% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (consolidated) — view original ↗

Price attractiveness

6.6/100

Is the price expensive relative to earnings?

Loss-making (P/E not computable)

Sector median P/E of profitable peers 13.9x · 29% loss-making

Sector low

highBottom 4% in sector

Is the price expensive relative to book value?

2.99x

Sector median 0.71x

Sector low

highBottom 9.2% in sector

Valuation uses the Sep 4, 2026 close and market cap

Shareholder Return

Single-indicator axis25.5/100

Does the company actually pay dividends?

0.0%

Sector median 0.0%

Sector low

highBottom 25.5% in sector

Dividends & treasury shares

Treasury shares (FY2025): 188,683 shares (0.5% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 7, 2026

Of 9 items: 4 met · 5 not met · 0 not computable

Not metMetNot computable

Positive net income

Whether net income (attributable to owners where available) is above zero.

Not met

-₩33.6B

Positive operating cash flow

Whether cash flow from operations is above zero.

Not met

-₩2.7B

Return on assets up

Whether net income over beginning total assets rose from the prior year.

Not met

0.6% → -25.3%

Operating cash flow exceeds net income

Whether operating cash flow is greater than net income.

Met

-₩2.7B vs -₩33.6B

Liabilities-to-assets ratio down

Whether total liabilities as a share of total assets fell from the prior year.

Not met

54.3% → 73.0%

Current ratio up

Whether current assets over current liabilities rose from the prior year.

Not met

85.3% → 58.8%

Shares outstanding not increased

Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.

Met

37,558,368 → 37,558,368

Operating margin up

Whether operating income over revenue rose from the prior year.

Met

-24.8% → -14.3%

Asset turnover up

Whether revenue over beginning total assets rose from the prior year.

Met

0.42x → 0.63x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026D→F

Methodology version change (v2.0 applied)

Jul 15, 2026DVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Large paid-in capital increase resolved

Disclosed a paid-in capital increase (제3자배정증자) issuing 24,177,949 new shares, equal to 64.4% of shares outstanding before the increase (filed 2026-09-03). View filing ↗

CB with conversion-price adjustment clause (past 36 months)

1 convertible bond (CB) issuance resolutions including a downward conversion-price adjustment (refixing) clause were disclosed in the past 36 months (latest filing 2025-08-22). View filing ↗

Management-dispute lawsuit filing

A filing under the KRX form “소송등의제기ㆍ신청(경영권분쟁소송)” (filing/petition of lawsuit — management dispute) was received (received 2026-03-09). View filing ↗

Financial fact combinations

Operating losses for 3 consecutive fiscal years

Recorded operating losses in three consecutive fiscal years, FY2023–FY2025 (per annual reports).

Determined as of 2026-09-07

Recent filings for this stock

Last 120 days · monitored filing types only

Paid-in capital increaseSep 3, 2026Source ↗

Periodic report filedAug 14, 2026Source ↗

Periodic report filedMay 15, 2026Source ↗

View in the filings calendar →